Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8NET8

UPID:
TRPV3_HUMAN

ALTERNATIVE NAMES:
Vanilloid receptor-like 3

ALTERNATIVE UPACC:
Q8NET8; Q8NDW7; Q8NET9; Q8NFH2

BACKGROUND:
The Transient receptor potential cation channel subfamily V member 3, or TRPV3, is a critical component in the sensory system, activated by warm temperatures and implicated in hair follicle regulation. Its ability to form associations with TRPV1 and influence keratinocyte proliferation in hair follicles positions TRPV3 as a key player in dermatological health.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of TRPV3 could open doors to potential therapeutic strategies for addressing rare congenital disorders like Olmsted syndrome 1 and focal palmoplantar keratoderma. By exploring TRPV3-targeted therapies, researchers are paving the way for groundbreaking treatments in dermatology.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.